{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:29:00Z","timestamp":1790681340051,"version":"4.1.0"},"reference-count":55,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2014,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Toxoplasmosis and amebiasis are important public health concerns worldwide. The drugs currently available to control these diseases have proven limitations. Therefore, innovative approaches should be adopted to identify and develop new leads from novel scaffolds exhibiting novel modes of action. In this paper, we describe results from the screening of compounds in the Medicines for Malaria Venture (MMV) open access Malaria Box in a search for new anti-\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Toxoplasma<\/jats:named-content>\n                    and anti-\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Entamoeba<\/jats:named-content>\n                    agents. Standard\n                    <jats:italic>in vitro<\/jats:italic>\n                    phenotypic screening procedures were adopted to assess their biological activities. Seven anti-\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Toxoplasma<\/jats:named-content>\n                    compounds with a 50% inhibitory concentration (IC\n                    <jats:sub>50<\/jats:sub>\n                    ) of &lt;5 \u03bcM and selectivity indexes (SI) of &gt;6 were identified. The most interesting compound was MMV007791, a piperazine acetamide, which has an IC\n                    <jats:sub>50<\/jats:sub>\n                    of 0.19 \u03bcM and a selectivity index of &gt;157. Also, we identified two compounds, MMV666600 and MMV006861, with modest activities against\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Entamoeba histolytica<\/jats:named-content>\n                    , with IC\n                    <jats:sub>50<\/jats:sub>\n                    s of 10.66 \u03bcM and 15.58 \u03bcM, respectively. The anti-\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Toxoplasma<\/jats:named-content>\n                    compounds identified in this study belong to scaffold types different from those of currently used drugs, underscoring their novelty and potential as starting points for the development of new antitoxoplasmosis drugs with novel modes of action.\n                  <\/jats:p>","DOI":"10.1128\/aac.02541-14","type":"journal-article","created":{"date-parts":[[2014,7,21]],"date-time":"2014-07-21T23:15:21Z","timestamp":1405984521000},"page":"5848-5854","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":67,"title":["Repurposing the Open Access Malaria Box To Discover Potent Inhibitors of Toxoplasma gondii and Entamoeba histolytica"],"prefix":"10.1128","volume":"58","author":[{"given":"Fabrice F.","family":"Boyom","sequence":"first","affiliation":[{"name":"Antimicrobial Agents Unit, Laboratory for Phytobiochemistry and Medicinal Plants Studies, University of Yaound\u00e9 I, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick V. T.","family":"Fokou","sequence":"additional","affiliation":[{"name":"Antimicrobial Agents Unit, Laboratory for Phytobiochemistry and Medicinal Plants Studies, University of Yaound\u00e9 I, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauve R. Y.","family":"Tchokouaha","sequence":"additional","affiliation":[{"name":"Antimicrobial Agents Unit, Laboratory for Phytobiochemistry and Medicinal Plants Studies, University of Yaound\u00e9 I, Yaound\u00e9, Cameroon"},{"name":"Institute of Medical Research and Medicinal Plants Studies (IMPM), Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Spangenberg","sequence":"additional","affiliation":[{"name":"Medicines for Malaria Venture, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvine N.","family":"Mfopa","sequence":"additional","affiliation":[{"name":"Antimicrobial Agents Unit, Laboratory for Phytobiochemistry and Medicinal Plants Studies, University of Yaound\u00e9 I, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruffin M. T.","family":"Kouipou","sequence":"additional","affiliation":[{"name":"Antimicrobial Agents Unit, Laboratory for Phytobiochemistry and Medicinal Plants Studies, University of Yaound\u00e9 I, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cedric J.","family":"Mbouna","sequence":"additional","affiliation":[{"name":"Antimicrobial Agents Unit, Laboratory for Phytobiochemistry and Medicinal Plants Studies, University of Yaound\u00e9 I, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie F. Donkeng","family":"Donfack","sequence":"additional","affiliation":[{"name":"Antimicrobial Agents Unit, Laboratory for Phytobiochemistry and Medicinal Plants Studies, University of Yaound\u00e9 I, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul H. A.","family":"Zollo","sequence":"additional","affiliation":[{"name":"Antimicrobial Agents Unit, Laboratory for Phytobiochemistry and Medicinal Plants Studies, University of Yaound\u00e9 I, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.2174\/1874104501105010001"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/1756-3305-6-75"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1076\/ocii.10.1.1.10330"},{"key":"e_1_3_3_5_2","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0002-9394(14)73976-5","article-title":"An unusually high prevalence of ocular toxoplasmosis in southern Brazil","volume":"114","author":"Glasner PD","year":"1992","unstructured":"GlasnerPDSilveiraCKruszon-MoranDMartinsMCBurnierMJrSilveiraSCamargoMENussenblattRBKaslowRABelfortRJr. 1992. An unusually high prevalence of ocular toxoplasmosis in southern Brazil. Am. J. Ophthalmol. 114:136\u2013144.","journal-title":"Am. J. Ophthalmol."},{"key":"e_1_3_3_6_2","first-page":"1","article-title":"Histopathological features of ocular toxoplasmosis in the fetus and infant","volume":"119","author":"Roberts F","year":"2001","unstructured":"RobertsFMetsMBFergusonDJO'GradyRO'GradyCThulliezPBrezinAPMcLeodR. 2001. Histopathological features of ocular toxoplasmosis in the fetus and infant. Arch. Ophthalmol. 119:1\u201358.","journal-title":"Arch. Ophthalmol."},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.3347\/kjp.2009.47.2.125"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9394(88)90382-0"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2010.09-0664"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1701.P11101"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-116-1-33"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1086\/340577"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1080\/09273940600659740"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2009.06.008"},{"key":"e_1_3_3_15_2","first-page":"115","article-title":"Drug resistance in amoebiasis","volume":"123","author":"Bansal D","year":"2006","unstructured":"BansalDMallaNMahajanIndianRC. 2006. Drug resistance in amoebiasis. Indian J. Med. Res. 123:115\u2013118.","journal-title":"Indian J. Med. Res."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00004-07"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12830-9"},{"key":"e_1_3_3_18_2","first-page":"3097","volume-title":"Principles and practice of infectious diseases","author":"Ravdin JI","year":"2005","unstructured":"RavdinJIStaufferWM. 2005. Entamoeba histolytica (amoebiasis), p 3097\u20133111. In MandellGLBennettJEDolinR (ed), Principles and practice of infectious diseases, vol 2. Churchill Livingstone, Philadelphia, PA."},{"key":"e_1_3_3_19_2","first-page":"13","article-title":"WHO\/PAHO\/UNESCO report: a consultation with experts on amoebiasis. Mexico City, Mexico 28-29 January 1997","volume":"18","author":"WHO","year":"1997","unstructured":"WHO. 1997. WHO\/PAHO\/UNESCO report: a consultation with experts on amoebiasis. Mexico City, Mexico 28-29 January 1997. Epidemiol. Bull. 18:13\u201314.","journal-title":"Epidemiol. Bull."},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exppara.2005.03.023"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000175"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1179\/136485910X12607012373911"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001318"},{"key":"e_1_3_3_24_2","first-page":"301","article-title":"Current pharmacotherapy of amebiasis, advances in new drugs, and design of a vaccine","volume":"53","author":"Chac\u00edn-Bonilla L","year":"2012","unstructured":"Chac\u00edn-BonillaL. 2012. Current pharmacotherapy of amebiasis, advances in new drugs, and design of a vaccine. Invest. Clin. 53:301\u2013314. (In Spanish.)","journal-title":"Invest. Clin."},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0062906"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1824"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1242\/jeb.00589"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0020-7519(98)00193-3"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro1048"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1153"},{"key":"e_1_3_3_31_2","first-page":"P06","article-title":"Drug development for tropical diseases\u2014present situation, future perspectives","volume":"19","author":"Horton J","year":"2003","unstructured":"HortonJ. 2003. Drug development for tropical diseases\u2014present situation, future perspectives. Trends Parasitol. 19:P06.","journal-title":"Trends Parasitol."},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1941.02820090001001"},{"key":"e_1_3_3_33_2","doi-asserted-by":"crossref","first-page":"402","DOI":"10.4269\/ajtmh.1977.26.402","article-title":"Experimental amebiasis. II. Hepatic amebiasis in the newborn hamster","volume":"26","author":"Mattern CF","year":"1977","unstructured":"MatternCFKeisterDB. 1977. Experimental amebiasis. II. Hepatic amebiasis in the newborn hamster. Am. J. Trop. Med. Hyg. 26:402\u2013411.","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exppara.2008.10.006"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.6.1810-1814.2001"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1208069109"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkf251"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm9017724"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm0602559"},{"key":"e_1_3_3_40_2","unstructured":"HedstromLKStriepenB. June 2007. IMP dehydrogenase inhibitors for treating mammalian gastrointestinal parasitic infections. Patent WO2007143557."},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules17022248"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.5012\/bkcs.2011.32.10.3666"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02641-13"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e31804b3f0d"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.04.020"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2005.05.025"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01500-13"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00044-012-0347-9"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.9.2575-2577.2000"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00436-013-3574-1"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00895-06"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01001-09"},{"key":"e_1_3_3_53_2","doi-asserted-by":"crossref","first-page":"381","DOI":"10.4269\/ajtmh.2007.77.381","article-title":"Experience with intravenous metronidazole to treat moderate-to-severe amebiasis in Japan","volume":"77","author":"Kimura M","year":"2007","unstructured":"KimuraMNakamuraTNawaY. 2007. Experience with intravenous metronidazole to treat moderate-to-severe amebiasis in Japan. Am. J. Trop. Med. Hyg. 77:381\u2013385.","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcl.2005.02.012"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpddr.2012.05.002"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2758"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02541-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02541-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T17:48:06Z","timestamp":1645465686000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02541-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":55,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["10.1128\/AAC.02541-14"],"URL":"https:\/\/doi.org\/10.1128\/aac.02541-14","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718502199.793524160","asserted-by":"object"}]},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"2014-02-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-07-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-09-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}